Why is the former CFO, Eva C. Boratto, receiving 22 months of continued salary?

The 22 months of continued base salary is part of the separation agreement negotiated between Ms. Boratto and CVS Health, likely to ensure a smooth transition and acknowledge her contributions while providing her with financial security during her departure.

What happens to Ms. Boratto's equity awards (stock options, RSUs, PSUs) after her departure?

Ms. Boratto's stock options will continue to vest and remain exercisable for up to three years after her separation date. Her restricted stock units will continue to vest through the salary continuation period and settle on their original vesting dates. Her performance stock unit awards will vest on a pro-rated basis through her separation date and settle on their original vesting dates.

Is Ms. Boratto subject to any ongoing restrictions after her separation?

Yes, the separation agreement incorporates by reference existing restrictive covenants, including non-competition and non-solicitation clauses, which Ms. Boratto is still bound by. The agreement also includes customary confidentiality and cooperation covenants.

Does this filing indicate a change in CVS Health's financial strategy or performance?

This 8-K filing is primarily focused on an executive departure and the terms of that separation. It does not, in itself, provide information on the company's broader financial strategy or current performance. Such information is typically found in quarterly earnings reports (10-Q) or annual reports (10-K).

CVS 8-K: Leadership Changes

Summary

CVS Health Corporation (CVS) filed an 8-K report on June 10, 2021, primarily detailing the departure of its former Executive Vice President and Chief Financial Officer, Eva C. Boratto, and the associated separation agreement. Ms. Boratto stepped down from her CFO role on May 28, 2021, but will continue in a senior advisory capacity to the CEO through December 1, 2021, to ensure a smooth transition. The separation agreement outlines significant post-employment benefits for Ms. Boratto, including 22 months of continued base salary, continued vesting and extended exercisability of stock options for three years, and continued vesting of restricted stock units through the salary continuation period. She will also receive a pro-rated bonus for 2021 and reimbursement for certain transition-related expenses. This filing provides clarity on the executive transition and the financial arrangements impacting the company.

Key Highlights

1Former CFO Eva C. Boratto stepped down on May 28, 2021.
2Ms. Boratto will serve in a senior advisory role until December 1, 2021, to assist with transition.
3A separation agreement provides Ms. Boratto with 22 months of continued base salary.
4Ms. Boratto's stock options will continue to vest and remain exercisable for up to three years post-separation.
5Restricted stock units will continue to vest through the salary continuation period.
6Performance stock unit awards will vest on a pro-rated basis through the separation date.
7The agreement includes a pro-rated bonus for 2021 and reimbursement of up to $90,000 in transition expenses.

CVS HEALTH Corp 8-K Report, Executive Changes (Jun 10, 2021)

Summary

Key Highlights

Frequently Asked Questions